Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.
Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW. · 2019
Read Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. by Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6675736.txt.
Introduction
Battle and co-authors map the global burden of Plasmodium vivax malaria from 2000 to 2017. Their modelling study appears in The Lancet. Vivax is the most widespread malaria species. Its burden had never been mapped at fine scale. The team adjusted routine surveillance data for known biases. Bayesian geospatial models predicted incidence and prevalence. African estimates leaned on falciparum surfaces and ratios. The maps feed the Global Burden of Disease 2017 study.
Global cases fell by 41.6 percent over the period. They dropped from 24.5 million to 14.3 million. The Americas cut cases by over half. South-East Asia and the Western Pacific matched that pace. Europe reached zero cases entirely. Declines stalled recently in many countries, though.
Catalog record
| CREATOR | Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study By Katherine E Battle, Tim C D Lucas, Michele Nguyen, Rosalind E Howes, Anita K Nandi, Katherine A Twohig, Daniel A Pfeffer, Ewan Cameron, Puja C Rao, Daniel Casey, Harry S Gibson, Jennifer A Rozier Published in: Lancet (London, England) DOI: 10.1016/S0140-6736(19)31096-7 ABSTRACT Summary Background Plasmodium vivax exacts a significant toll on health worldwide, yet few efforts to date have quantified the extent and temporal trends of its global distribution. Given the challenges associated with the proper diagnosis and treatment of P vivax, national malaria programmes—particularly those pursuing malaria elimination strategies—require up to date assessments of P vivax endemicity and disease impact. This study presents the first global maps of P vivax clinical burden from 2000 to 2017. Methods In this spatial and temporal modelling study, we adjusted routine malariometric surveillance data for known biases and used socioeconomic indicators to generate time series of the clinical burden of P vivax. These data informed Bayesian geospatial models, which produced fine-scale predictions of P vivax clinical incidence and infection prevalence over time. Within sub-Saharan Africa, where routine surveillance for P vivax is not standard practice, we combined predicted surfaces of Plasmodium falciparum with country-specific ratios of P vivax to P falciparum. These results were combined with surveillance-based outputs outside of Africa to generate global maps. Findings We present the first high-resolution maps of P vivax burden. These results are combined with those for P falciparum (published separately) to form the malaria estimates for the Global Burden of Disease 2017 study. The burden of P vivax malaria decreased by 41·6%, from 24·5 million cases (95% uncertainty interval 22·5–27·0) in 2000 to 14·3 million cases (13·7–15·0) in 2017. The Americas had a reduction of 56·8% (47·6–67·0) in total cases since 2000, while South-East Asia recorded declines of 50·5% (50·3–50·6) and the Western Pacific regions recorded declines of 51·3% (48·0–55·4). Europe achieved zero P vivax cases during the study period. Nonetheless, rates of decline have stalled in the past five years for many countries, with particular increases noted in regions affected by political and economic instability. Interpretation Our study highlights important spatial and temporal patterns in the clinical burden and prevalence of P vivax. Amid substantial progress worldwide, plateauing gains and areas of increased burden signal the potential for challenges that are greater than expected on the road to malaria elimination. These results support global monitoring systems and can inform the optimisation of diagnosis and treatment where P vivax has most impact. Funding Bill & Melinda Gates Foundation and the Wellcome Trust. INTRODUCTION Marked progress in malaria control has nearly halved deaths due to the disease since 2000 and reduced global incidence by more than 30%.1 Yet much of this progress was driven by a focus on Plasmodium falciparum malaria, the most prevalent and virulent malaria strain, which predominates in sub-Saharan Africa. To bring the global health community’s ambition of eradicating malaria by 2040 closer to reality,2 it is crucial to gain a greater understanding of the other five Plasmodium species known to cause human malaria.3 Plasmodium vivax is the most geographically widespread species and second largest contributor to clinical (symptomatic) malaria worldwide, yet historically, its place on the international health agenda has remained low. Once viewed as a benign infection, P vivax malaria is now recognised as a cause of severe morbidity and mortality, resulting in a substantial negative effect on health worldwide.4,5 Understanding the spatiotemporal distribution and clinical burden of P vivax is essential for effective control and elimination planning. P vivax often circulates in the peripheral blood at low, but transmissible, parasite densities. It also has the ability to form undetectable dormant liver stages (ie, hypnozoites), which can periodically awaken to cause recurrent infection and disease (relapse). Although 8-aminoquinoline drugs are effective against liver stage parasites, they can cause severe haemolytic anaemia in individuals with a glucose-6-phosphate dehydrogenase deficiency and are contraindicated in pregnant women and infants.6 Primaquine, the only widely available hypnozoiticide, is limited by poor adherence to the standard 14-day regimen and has reduced efficacy in patients with impaired cytochrome P-450 2D6 activity.7–9 The much-anticipated availability of tafenoquine will address some of these limitations but it remains a controlled therapy in the short-term, contingent on quantitative glucose-6-phosphate dehydrogenase screening, which is currently not widely available. Robust burden estimates can help identify areas where targeted use of such treatment should be a priority. Previous efforts to quantify the burden of P vivax malaria were derived from P falciparum or total malaria estimates, and varied widely. An estimate of 72–80 million cases was published in 200110 based on case numbers and regional ratios of P vivax to P falciparum infections reported to WHO. In 2007, Price and colleagues predicted 132–391 million cases based on non-falciparum malaria prevalence estimates generated by Hay and colleagues.11–13 In 2013, WHO began including P vivax case estimates in the World Malaria Report and then reported 11∙9–22∙0 million P vivax clinical cases for 2012.14 Establishing where precisely the true burden of P vivax malaria lies, with respect to the wide range of these conflicting estimates (12–390 million), has long been identified as a research priority.10,12,15 The aim of this analysis was to quantify and map clinical P vivax malaria cases and the prevalence of patent blood-stage infections in all P vivax endemic areas from 2000 to 2017. Building on previous analyses that mapped endemicity using cross-sectional survey data for infection prevalence,16 substantial methodological improvements allowed the wealth of information collected by routine surveillance activities to be used. As a result of these developments, P vivax was added to the Global Burden of Disease (GBD) cause list. The findings presented here, together with parallel work on P falciparum,17 informed the overall malaria estimates for the GBD 2017 study.18 Here, results are presented at a fine scale (5 × 5 km) and for P vivax alone. The maps and trends provide an evidence-base to track past and future progress towards national and regional milestones and to identify areas in which improved diagnosis and treatment efforts should be targeted on the path to malaria elimination. METHODS Overview Separate models were developed for P vivax clinical incidence and infection prevalence (parasite rate) within and outside Africa, reflecting the nature and quality of available data. A surveillance-based approach was primarily used for locations outside Africa, with clinical incidence modelled from routine surveillance reports obtained from country programmes (Malaria Atlas Project database) and the World Malaria Report. Time-series models generated national case counts that informed pixel-level clinical incidence predictions within endemic areas. A model of the relationship between clinical incidence and P vivax parasite rate converted fine-scale incidence into estimates of prevalence.19 Within Africa, data were not collected as part of routine surveillance or cross-sectional surveys across most of the continent due to the dominance of the host Duffy-negative blood group that was thought to prevent endemic transmission of the parasite.20,21 Estimates for P vivax in Africa therefore started with fine-scale estimates of P falciparum parasite rate derived from household survey data22,23 with a cartographic modelling approach.24 P falciparum incidence was modelled from these P falciparum parasite rate estimates,25 and then converted to P vivax-specific incidence using